Morphosys Ag (MOR) has released an update.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
MorphoSys AG has announced a delisting agreement with Novartis, following the latter’s successful acquisition and intent to merge with MorphoSys. Novartis, now holding over 91% of MorphoSys shares, plans to offer the remaining shareholders €68.00 per share to consolidate ownership. The transaction processes, including the delisting from Frankfurt Stock Exchange and NASDAQ, are expected to be completed in the third quarter of 2024.
For further insights into MOR stock, check out TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue